Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Atogepant, Placebo-matching Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

NCT01709825
View directory record Official record
Conditions
Healthy
Interventions
Probiotic- Bifidobacterium Bifidum, Sugar Pill, Probiotic- Lactobacillus helveticus, Probiotic- Bifidobacterium longum ss. Infantis R0033
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2Phase 3 Interventional

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

NCT01782989
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

NCT01425476
View directory record Official record
Conditions
Breast Cancer
Interventions
Celecoxib, Placebo, Cholecalciferol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 25, 2026, 11:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Skin Hydration in Persons With Acne After Dietary Supplementation With Botanical Antioxidants

NCT04534140
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
HBKB Capsule, HBKB Supplement Vehicle
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

NCT01706315
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

NCT02927184
View directory record Official record
Conditions
Hyperlipidemia, NAFLD
Interventions
VK2809, Placebo
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics

NCT01301521
View directory record Official record
Conditions
Diabetes, Pre-Diabetes
Interventions
water-soluble cinnamon extract (Cinnulin PF)
Drug
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Travis Air Force Base, California • Eglin Air Force Base, Florida • Offutt Air Force Base, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 25, 2026, 11:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin D3 Supplementation for Vitamin D Deficiency in Rotator Cuff Repair Surgery

NCT05009498
View directory record Official record
Conditions
Vitamin D Deficiency, Rotator Cuff Tears
Interventions
Vitamin D3 supplementation, Placebo
Dietary Supplement · Other
Lead sponsor
Community Memorial Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 25, 2026, 11:14 PM EDT
Recruiting Phase 1 Interventional

Post-Vasectomy Pain Study

NCT07824258
View directory record Official record
Conditions
Vasectomy, NSAIDs, Post-operative Care
Interventions
Acetaminophen, ibuprofen, oxycodone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

NCT02664558
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex, placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

NCT00847808
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR QD
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
52
States / cities
Hueytown, Alabama • Chandler, Arizona • Sierra Vista, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

NCT01545349
View directory record Official record
Conditions
Healthy, Influenza
Interventions
Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo, Live attenuated influenza vaccine
Biological
Lead sponsor
Patricia L. Hibberd
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 25, 2026, 11:14 PM EDT
Active, not recruiting Not applicable Interventional

Curcumin in Kidney Transplant Recipients

NCT03935958
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Curcumin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT03482648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 25, 2026, 11:14 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery

NCT04554693
View directory record Official record
Conditions
Endometriosis, Endometriosis-related Pain
Interventions
Metronidazole Oral, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

NCT01276106
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AC-201, 25mg, AC-201, 50mg, AC-201, 75mg, Placebo
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Chino, California • Los Angeles, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

NCT03897348
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Lacosamide 100 mg, Lacosamide 200 mg
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of SRX246 Capsules in Healthy Adult Volunteers

NCT00910455
View directory record Official record
Conditions
Healthy
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder

NCT01098435
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
RDC-0313 (ALKS 33), Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Tucson, Arizona • Minneapolis, Minnesota • Manlius, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 25, 2026, 11:14 PM EDT
Terminated Phase 4 Interventional Results available

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT04507204
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Adhansia XR, Concerta
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
12 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
35
States / cities
Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

NCT02708355
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 25, 2026, 11:14 PM EDT